Global Metabolic Disorders Therapeutics Market- Novo Nordisk, Sanofi, Merck

Global Metabolic Disorders Therapeutics Market is projected to grow with a CAGR between 4.8% and 5.3% over the forecast period of 2016-2022 and reach USD 200 billion by 2022.

Introduction:
The report segments the metabolic disorder therapeutics market by types of disease and by region. Market segmentation based on types of disease includes diabetes, obesity, hypercholesterolemia and lysosomal storage disease.

Do Inquiry Before Purchasing Report Here: https://market.biz/report/global-metabolic-disorders-therapeutics-market-gm/101589/#inquiry

In 2014, the Global Metabolic Disorder Therapeutics Market size was valued USD XX billion. While in 2015, the market size of metabolic disorder therapeutics was valued over USD XX million. The global metabolic disorder therapeutics market is projected to grow with a CAGR between 4.8% and 5.3% over the forecast period of 2016-2022 and reach USD 200 billion by 2022. Metabolism is a process in which human body generates energy from the food humans eat. The food that humans consume comprises proteins, carbohydrates, and fats. Chemicals in human digestive system break the food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in human body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by enzymes.

Segments Covered.
The report segments the metabolic disorder therapeutics market by types of disease and by region. Market segmentation based on types of disease includes diabetes, obesity, hypercholesterolemia and lysosomal storage disease. Among segments given above, diabetes drug segment was the leading segment and accounted for highest market share over 64% globally in 2015. The increasing diabetic population across the globe is one of the significant factors propelling the growth of this segment.

Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, and Rest of the World (RoW). North America was the largest market for metabolic disorder and likely to continue its dominance with a majority market shares globally over the period of 2014 to 2015. The US was the major contributor in the region, as half of the adult population in the country is suffering from diabetes over past couple of years. Following North America, Asia Pacific accounted to be the most prominent region for metabolic disorder over the forecast period. Healthcare reforms across the region and rising diabetic population especially in India are anticipated to boost the growth in the Asia – Pacific market.

The companies covered in the Global Metabolic Disorders Therapeutics Market report:
1) Novo Nordisk
2) Sanofi
3) Merck
4) AstraZeneca
5) Eli Lily
6) AbbVie
7) Actelion Pharmaceuticals
8) Amicus Therapeutics
9) Arena Pharmaceuticals
10) Astellas Pharma
11) Biocon
12) Biospherics
13) Boehringer Ingelheim
14) CKD Bio
15) Concord Biotech
16) ConjuChem
17) CureDm
18) CymaBay Therapeutics
19) Daewoong
20) Daiichi Sankyo
21) Dance Biopharm
22) DiaMedica

Request For Sample Report Here: https://market.biz/report/global-metabolic-disorders-therapeutics-market-gm/101589/#requestforsample

About Us:
Market.Biz consists of a highly motivated team of young and experienced individuals who are detail-oriented and highly focused on providing clients with the information they need. Information is king in the business world, and we specialize in providing that.

Referal News Network: http://publicistreport.com

Contact Info:
Name: Lawrence John
Email: Send Email
Organization: Market.Biz
Address: S no. 51/14 First Floor, Office Number 4, Vishwa Arcade, Near Navale Lawns, Pune, Maharashtra, India 411041.
Phone: +1(857)2390696
Website: https://market.biz/report/global-metabolic-disorders-therapeutics-market-gm/101589/

Release ID: 215046